BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Biotech Bay

  UCSF Researchers Develop Synthetic Llama Antibodies Against COVID-19

  They are approximately 25% of the size of human antibodies and from other animals, and they appear to be the most potent anti-coronavirus compound that has been tested in the laboratory so far.

  August 11, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Lone Star Bio

  With $95M in New Funding, Taysha Gene Therapies Looks to Advance Pipeline

  Texas-based Taysha Gene Therapies announced last week that it had concluded a Series B round of financing worth $95 million.

  August 11, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  Lone Star Bio

  Reata Pharmaceuticals Sees Hiccup in Filing for Approval of FA Drug

  Texas-based Reata Pharmaceuticals announced the potential delay Monday when it released its 2nd quarter financial report.

  August 11, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform

  Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.

  August 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Bayer Bolsters Women’s Health Pipeline with Acquisition of KaNDy Therapeutics

  With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.

  August 11, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Veru’s Compound Shows Promise as Antiviral/Anti-Inflammatory Therapeutic for COVID-19

  Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe COVID-19 infections.

  August 11, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies

  Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of its checkpoint inhibitor Opdivo (nivolumab).

  August 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Russia Approves COVID-19 Vaccine Ahead of Phase III Studies

  The government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus.

  August 11, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  New Drug Discovery Process Could Significantly Cut Development Time

  Simon Fraser University chemist Robert Britton and a team of international researchers believe that their findings could lead to a more efficient way of discovering drugs for newly evolved viruses as well, such as the SARS-CoV-2 (COVID-19).

  August 11, 2020

   · 

  2 min read

   · 

  Krystle Vermes
• 

  Genetown

  Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

  Biogen recently announced plans to initiate a Phase IV clinical trial to determine the benefit of Spinraza in patients who received Zolgensma. The two therapies have markedly different ways of treating the disease.

  August 11, 2020

   · 

  4 min read

   · 

  Mark Terry